How Medicare Part D Pays: The Pharmacy Receipt Is Only the Beginning

Medicare Part D payment reconciliation uses prescription drug event records and direct and indirect remuneration reports to settle federal payments against the drug costs a plan actually incurred. The pharmacy transaction sits inside a longer account: what the patient paid, what the plan reported, what manufacturers returned in rebates and what Medicare ultimately owed. If you work inside a pharmacy, health plan or pharmacy benefit manager, you may see where those accounts stop agreeing. The useful question is which number reached Medicare, and who knew it needed to change.

Why a Pharmacy Receipt Is Not the Final Part D Bill

The Centers for Medicare & Medicaid Services’ published drug-event example for 2025 follows a $400 prescription that moves a beneficiary from initial coverage into catastrophic coverage. It assigns $60 to the patient, $56 to the manufacturer discount and $284 to Covered D Plan Paid Amount.

Within that event, the catastrophic portion of the plan-paid amount is $128, representing 80% of the drug cost above the threshold. That is the amount reported in that field before federal reinsurance. It is not the sponsor’s final share of the year’s costs.

The pharmacy transaction, the drug-event report and the annual federal adjustment answer different questions. A number labeled plan paid can still include costs that Medicare will help cover. Rebates can reduce the cost again. We follow those changes because taxpayers’ exposure sits at the end of that calculation, not on the pharmacy receipt.

Who Pays Whom in Medicare Part D?

Medicare and beneficiaries pay private Part D sponsors to provide prescription drug coverage through stand-alone plans or the drug component of Medicare Advantage plans. A pharmacy submits its transaction through the plan or its pharmacy benefit manager. The plan determines how the prescription is paid, and the sponsor reports prescription drug event data to Medicare. A PBM may perform delegated functions, but the sponsor remains responsible for its Medicare contract.

Manufacturer rebates and other price concessions enter another part of the account. They can reduce the sponsor’s drug cost after the pharmacy transaction. Medicare needs both sets of data to calculate its payment toward those health care costs. The pharmacy’s view of the transaction is valuable precisely because it can be compared with what the sponsor later reported.

The payer distinction also matters when someone has both Medicare and Medicaid coverage. Part D remains a Medicare payment system. Low-income assistance within Part D is part of its federal financing, with its own payment records.

The drug as prescribed, dispensed or administered determines whether its payment belongs under Part D or Part B.

From the Bid to the Monthly Payment

The sponsor’s certified bid and actuarial valuation estimate the revenue needed for the coming year’s benefit at a national-average risk profile.

The ordinary bid includes benefits for which the sponsor is responsible, administration and a return or profit. It excludes beneficiary cost sharing and projected federal reinsurance. CMS risk-adjusts the approved standardized bid and subtracts the applicable beneficiary premium component to calculate the direct subsidy. Enrollment and risk information therefore matter alongside the bid itself.

Other monthly payments advance estimated reinsurance and low-income cost-sharing subsidies. Starting in 2026, the selected-drug subsidy adds another prospective payment stream. In its instructions for that year, CMS explains the cash-flow reason: some expenses become fully known only after the year, while plans need money to cover them during the year.

The bid shows the forecast. Monthly payment reports show what Medicare advanced. Reconciliation compares those payments with the costs used in the final calculation. A finance employee can see where the business changed its account of what it needed or spent.

The Congressional Research Service identified inappropriate overestimation or underestimation of bids among the risks in advance-paid Medicare plans in its 2011 report on program integrity. The payment story starts with what the sponsor said it would need, before reaching what it later said it spent.

How PDE Records Affect Medicare Part D Payment

PDE records affect Medicare Part D payment by supplying the drug-cost and payer information CMS uses in annual reconciliation. A prescription drug event is the sponsor’s report of the covered transaction, with fields that distinguish the amounts and benefit phases involved.

The CMS example separates ingredient cost, dispensing fee, patient pay, low-income cost-sharing subsidy, other-payer amounts, manufacturer discount and plan-paid amount. It also records accumulated drug spending, accumulated true out-of-pocket costs and the beginning and ending benefit phases. A prescription crossing into catastrophic coverage therefore has costs on both sides of the threshold within the same event.

Qualifying out-of-pocket spending advances the beneficiary toward the annual threshold. In this example, the beneficiary’s payment counts toward that threshold and the manufacturer’s discount does not.

Processing history matters too. Submitted, accepted and rejected PDEs, along with adjustments and deletions, belong in the event’s history. CMS’s notice completing the 2022 reconciliation used accepted PDEs through a specified processing cycle. It excluded events for beneficiaries retroactively disenrolled with no Part D coverage on the service date. It also excluded service dates more than 14 days after death for home residents using community or retail pharmacies, or more than 32 days after death otherwise. An accepted event could still be left out of the payment calculation.

What DIR Changes After the Prescription

Direct and indirect remuneration lowers the drug costs used to calculate federal payments. DIR reaches beyond checks labeled manufacturer rebates. CMS’s 2025 instructions include discounts, chargebacks, purchase-linked free goods, coupons, grants and other concessions that reduce the sponsor’s cost.

Where a concession appears matters. MedPAC’s July 2026 Data Book attributed a decline in reported postsale DIR to pharmacy concessions moving into the point-of-sale price in 2024. For an insider comparing years, the pharmacy price and the later remuneration report must be read together. A saving can move from one record to another.

What Is the Difference Between Summary DIR and Detailed DIR?

Summary DIR supplies remuneration information used in payment reconciliation. Detailed DIR reports at the contract, plan benefit package and eleven-digit National Drug Code level for the branded-drug manufacturer fee process.

The Centers for Medicare & Medicaid Services’ annual attestation instructions distinguish the payment certification covering prescription drug events and Summary DIR from the Detailed DIR certification. The latter also requires the sponsor to obtain certifications from entities that generated its Detailed DIR data.

When a Rebate Is Called a Service Fee

Rite Aid and Elixir Insurance Company agreed to pay $101 million in a civil settlement announced in July 2024. The Justice Department alleged that portions of manufacturer rebates were improperly reported as bona fide service fees between 2014 and 2020, and that Elixir knew the retained rebates did not meet that definition.

Medicare relied on those annual reports to determine amounts due to the plans or the government. A former employee brought the whistleblower claims resolved in the settlement. The department’s Civil Division and the U.S. Attorney’s Office for the Northern District of Ohio handled the matter, with substantial investigative assistance from the Department of Health and Human Services inspector general and the FBI’s Cleveland office.

We see the absurdity in the allegation: the business allegedly kept the rebate while asking Medicare to pay as though that saving did not count. The label had a taxpayer on the other end.

How Medicare Part D Payment Reconciliation Works

Medicare Part D payment reconciliation uses PDE costs and DIR to calculate final subsidies and risk-corridor amounts, then compares them with payments advanced during the year. Reinsurance and risk corridors use different calculations.

Part D Federal Reinsurance Reconciliation

Part D federal reinsurance reconciliation compares the final reinsurance subsidy with the amounts CMS advanced during the coverage year. The final calculation uses eligible catastrophic costs after an allocation of DIR.

Under the 2025 methodology, CMS totals catastrophic costs from prescription drug events at the plan level. It allocates remuneration using the ratio of total DIR to allowable reinsurance costs across applicable and non-applicable drugs. That denominator covers catastrophic costs. CMS subtracts the allocated remuneration before applying the federal share. The share is 20% for applicable drugs under the Manufacturer Discount Program and 40% for non-applicable drugs.

The remaining remuneration enters the risk-corridor cost calculation. That is why the rebate report matters to more than a pharmacy’s reimbursement or the PBM’s revenue. It changes the costs against which Medicare settles with the sponsor.

For the selected-drug subsidy introduced in 2026, CMS compares prospective payments with actual subsidy amounts reported on PDEs. Its instructions provide for an additional payment when actual subsidy costs exceed advances, or recovery when advances exceed actual costs.

Part D Risk Corridors and Rebates

Part D risk corridors and rebates meet in the comparison between adjusted allowable costs and the plan’s bid-based target. Risk corridors share specified gains or losses between the plan and the government around that target.

CMS excludes administrative expenses from this comparison. It also accounts for federal reinsurance, low-income cost-sharing payments and DIR, and adjusts for the effect of supplemental coverage on utilization.

The premium-stabilization demonstration changed upper-side risk sharing for participating stand-alone plans in 2025. CMS removed the narrowed risk corridors for 2026. The coverage year and the plan’s participation therefore belong beside the bid and cost records when we examine the adjustment.

CMS calculates that target from payments based on the standardized bid, including payments from Medicare and from or on behalf of enrollees, less the administration assumed in the bid. The comparison therefore joins the original revenue assumptions to the later allowable costs.

What the Officer Signs

For the 2025 reconciliation, the Centers for Medicare & Medicaid Services required the sponsor’s chief executive, chief financial officer or chief operating officer to sign the annual attestations electronically. The payment attestation certifies that prescription drug event data, Summary DIR and other information used for reinsurance and risk corridors are accurate, complete and truthful. It also acknowledges their use to obtain federal reimbursement.

The plan-to-plan worksheet and its attestation identify which contracts owed and received money, the amounts owed and paid, and any difference.

An attachment can describe a prescription drug event error already reported to CMS and being corrected, including its size and expected resolution. That puts the business’s account of a known problem beside its officer’s certification.

Reconciliation can produce an additional payment or a recovery, and later corrections can change the result. CMS can reopen a finished reconciliation. The calculation report, payment adjustment and correction history show what happened to the money at each stage.

Why the Coverage Year Controls the Calculation

The Part D redesign changed who bears drug costs in stages. The standard benefit’s deductible and out-of-pocket threshold also changed, so the date of the prescription belongs beside every payment calculation.

In 2024, the standard deductible was $545 and the qualifying out-of-pocket threshold was $8,000. Beneficiary coinsurance ended in catastrophic coverage, while the coverage gap remained. Sponsors bore 20% of catastrophic costs and federal reinsurance covered the rest.

In 2025, the standard deductible became $590 and the annual threshold fell to $2,000. The coverage gap disappeared and the Manufacturer Discount Program began. For ordinary applicable drugs in catastrophic coverage, the sponsor share became 60% and manufacturers took a share alongside federal reinsurance. The plan-paid field in the opening example precedes that federal allocation.

In 2026, the standard deductible is $615 and the annual threshold is $2,100. Negotiated prices first apply to selected drugs. For those drugs, the new federal selected-drug subsidy covers 10% of the negotiated price in initial coverage once its eligibility conditions are met. Selected drugs receive the higher reinsurance rate described above in catastrophic coverage, instead of the ordinary manufacturer-discount allocation.

For 2027, the 2026 Medicare Trustees report identifies a finalized standard deductible of $700 and annual threshold of $2,400. Those are next year’s parameters.

What the Records Can Show

The strongest Medicare fraud evidence connects the underlying prescription, the submitted information, the payment effect and the decision inside the business. A dispensing record or reversal begins one comparison. The accepted drug-event record and any adjustment show what reached CMS. Rebate records and DIR reporting show how the cost changed afterward.

Bid assumptions, monthly payment reports, officer certifications and reconciliation reports complete other parts of that account. A warning sent to management can explain when the business knew about a mismatch. The response and later submissions show what it did with that knowledge. We work through those connections with the person who understands the operation.

Public data can help locate a healthcare fraud pattern worth examining. The 2018 Journal of Big Data study Big Data fraud detection using multiple medicare data sources used public Part D data that aggregated prescribing by provider and drug. An insider’s event, rebate and reconciliation records supply a much closer view of the payment.

CMS’s own Part D payment review compares the prescribed drug, the dispensed drug and the PDE. Its fiscal 2025 findings identified missing or invalid documentation, drug discrepancies and pricing discrepancies in a review based on 2023 payments. Our inquiry follows the discrepancy through to the federal calculation and the people who understood it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Numbers Changed

If you know why a prescription, rebate or correction reached Medicare with the wrong information, speak to one of our Whistleblower Experts about the payment behind it. We connect the pharmacy and plan records to the federal money and bring in Medicare Part D fraud whistleblower lawyers to build your strongest Part D whistleblower case. You know the business, and we stay beside you through the case.